UI Hospitals and Clinics

Clinical Trial Details

Short Title
Exelixis METEOR 2nd line Cabozantinib (XL184) vs Everolimus in RCC
Official Title
  A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Description

Participants in this study are diagnosed with renal cell cancer (RCC). The purpose of this study is to evaluate the effect of study drug cabozantinib compared with everolimus on overall survival (OS) and progression-free survival (PFS) in subjects with advanced RCC. This study will be take place at approximately 200 global clinical sites with a total of about 650 participants. Approximately 9 participants will take part in this study at the University of Iowa.

Start Date
May 9, 2014
End Date
May 1, 2015
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Daniel Vaena, MD
Contact Info

Julie Schlabaugh      Julie-Schlabaugh@uiowa.edu

Department
Hematology/Onocology
Keywords
Cabozantinib ; Cancer ; Everolimus ; Phase 3 ; Phase III ; Renal Cell ; Vaena ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.